Results 31 to 40 of about 5,090 (179)

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]

, 2020
PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P, Andtbacka, Robert HI, Arlauckas, Sean P, Ballesteros-Merino, Carmen, Bannavong, Donna, Bhatia, Shailender, Bifulco, Carlos, Browning, Erica, Canton, David A, Daud, Adil I, Fong, Lawrence, Fox, Bernard A, Francisco, Murray, Gargosky, Sharron, Garris, Christopher, Hermiz, Reneta, Le, Mai, Levine, Lauren P, Oglesby, Arielle, Pierce, Robert, Pittet, Mikael J, Rosenblum, Michael D, Tsai, Katy K, Twitty, Christopher G   +23 more
core   +2 more sources

A practical guide to the handling and administration of talimogene laherparepvec in Europe. [PDF]

, 2017
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe.
Dummer, R., Frauchiger, A.L., Grove, L., Harrington, K.J., Malvehy, J., Michielin, O., Pezzani Grüter, I.   +6 more
core   +4 more sources

Biological therapy in the treatment of melanoma [PDF]

, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile, Georgescu, Simona Roxana, Ghita, Ela, Ioghen, Mihaela Roxana, Ion, Alexandra-Florentina, Mitran, Cristina-Iulia, Mitran, Madalina-Irina, Sarbu, Maria Isabela, Tampa, Mircea   +8 more
core   +3 more sources

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Journal for ImmunoTherapy of Cancer, 2018
Background Immune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized, including combining immune ...
David M. Miller, Ryan M. Trowbridge, Anupam Desai, Reed E. Drews   +3 more
doaj   +1 more source

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. [PDF]

, 2016
Several immunomodulatory checkpoint inhibitors have been approved for the treatment of patients with advanced melanoma, including ipilimumab, nivolumab and pembrolizumab.
Ascierto, P.A., Blank, C.U., Hoeller, C., Michielin, O., Szabo, Z.   +4 more
core   +1 more source

Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis

Virology Journal, 2021
Background Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a ...
Ruiyang Xie, Xingang Bi, Bingqing Shang, Aiping Zhou, Hongzhe Shi, Jianzhong Shou   +5 more
doaj   +1 more source

Immunotherapy for Esophageal Squamous Cell Carcinoma [PDF]

, 2017
Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies.
Takashi Kojima, Toshihiko Doi
core   +1 more source

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1 [PDF]

, 2014
Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system.
Bernd Heinrich, Caroline J. Breitbach, Jean Rommelaere, Katrin Goepfert, Maike Delic, Markus Moehler, Peter Robert Galle   +6 more
core   +2 more sources

The importance for immunoregulation for long-term cancer control. [PDF]

, 2017
Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma, the combination of ipilimumab with nivolumab showed high efficacy.
Alberto Fusi, Angus Dalgleish, Chan TA, Chen RW, Fryer RA, Hyunjoon K, Weber J   +6 more
core   +1 more source

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. [PDF]

, 2021
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe.
Aedo-Lopez, V., Hafner, C., Hoeller, C., Karasek, M., Kehrer, H., Koch, L., Koelblinger, P., Kofler, J., Latifyan, S., Mangana, J., Michielin, O., Posch, C., Ressler, J.M., Richtig, E., Silmbrod, R., Weihsengruber, F.   +15 more
core   +2 more sources